1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Sunder Biomedical Tech. Co., Ltd.

Sunder Biomedical Tech. Co., Ltd.

TTPEX:4115
7.15
TWD
-0.18
(-2.46%)
463.80MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.64
14.11
15.18
18.99
17.56
12.84
12.78
12.56
- -
Basic EPS, GAAP
0.08
0.23
0.88
1.18
0.22
-0.55
0.48
-0.27
- -
Free Cash Flow per Basic Share
-2.67
-0.5
-0.57
1.39
0.51
-0.23
0.17
-0.13
- -
Dividend per Share
- -
- -
- -
0.3
0.6
0.3
- -
- -
- -
Book Value per Share
11.49
11.63
12.59
13.48
13.17
12.26
12.96
12.63
12.89
Tangible Book Value per Share
11.45
11.6
12.56
13.45
13.13
12.23
12.92
12.58
12.84
Basic Weighted Avg Shares
59
60
60
60
60
60
60
60
60
Sales/Revenue/Turnover
802
842
911
1,140
1,054
770
767
753
- -
Operating Margin (%)
2.1
3.48
6.9
7.1
1.47
-4.86
3.14
-2.3
- -
Depreciation Expense
58
79
86
96
104
105
84
87
- -
Net Income, GAAP
5
14
53
71
13
-33
29
-16
- -
Effective Tax Rate (%)
11.03
17.96
11.04
19.04
- -
- -
4.33
- -
- -
Profit Margin (%)
0.59
1.63
5.77
6.24
1.26
-4.3
3.79
-2.16
- -
Working Capital
65
26
129
176
206
228
169
117
100
LT Debt
184
162
256
239
250
228
158
136
107
Total Equity
689
698
755
809
790
736
777
758
774
Return on Invested Capital (%)
- -
2.11
4.34
4.84
- -
- -
1.92
- -
- -
Return on Capital (%)
- -
2
4.79
5.83
- -
- -
3.29
- -
- -
Return on Common Equity (%)
- -
1.98
7.23
9.08
1.67
-4.34
3.85
-2.12
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
242
253
294
LT Borrowings
112
132
104
LT Finance Leases
5
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
559
504
464

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
465
490
517
Cash, Cash Equivalents & STI
120
122
114
Accounts Receivable, Net
224
236
233
Inventories
112
119
152
Total Current Liabilities
351
373
417
Payables & Accruals
- -
- -
- -
ST Debt
242
253
294
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
0.21%
-2.51%
Free Cash Flow
- -
-180.2%
-178.68%
Net Income, GAAP
- -
-147.74%
-155.88%
Sales/Revenue/Turnover
- -
-2.3%
-1.74%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
767
2025
- -
- -
753
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.48
2025
- -
- -
-0.27
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yuan Chi Yu
Full Time Employees
346
Sector
Health technology
Industry
Medical specialties
Address
No. 16, Chung-Chen Road Taichung Taiwan
IPO Date
Aug 31, 2022
Website
sunder.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sunder Biomedical Tech. Co., Ltd. (4115.TWO) manufactures and sells disposable medical devices and consumables for surgical, endoscopic, hemodialysis, and infusion procedures. The company offers endoscopy vision auxiliary sets, suction irrigation sets, smoke filters, endoscopic retrieval bags; blood line sets for hemodialysis, A.V. fistula needle sets, transducer protectors; I.V. administration sets, volume control I.V. administration sets, extension tubes, surgical tubing sets; medical-grade PVC compounds, components such as caps for dialyzer adaptors and female luer locks; meltblown nonwoven fabrics and masks, protective goggles; and laboratory testing and sterilization services. Sunder Biomedical operates primarily in the healthcare equipment and supplies industry, serving hospitals, clinics, laboratories, and medical facilities worldwide, with key markets in Southeast Asia, China, South Korea, Russia, Pakistan, Peru, and Bolivia. Founded in 1998 and headquartered in Pao-Chung Township, Yunlin County, Taiwan, the company maintains a manufacturing facility with GMP and ISO 13485 certifications, including ISO 8 clean rooms and advanced production lines. In a recent strategic divestiture, Medimaging Integrated Solution Inc. agreed to acquire LIAN CHAN PRECISION CO., LTD. from Sunder Biomedical for TWD 66 million in 2024, reflecting portfolio optimization efforts. Additionally, the company pursues capacity expansion through investments exceeding TWD 1.2 billion in high-value hemodialysis catheter production and R&D facilities in Taiwan as part of 2025 repatriation initiatives.